Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the US

Shots:

• The approval is based on the study assessing Egaten (triclabendazole) in patients with fascioliasis aged ≥ 6yrs.
• Novartis’ Egaten is in use since 2005 by WH, serving 2M fascioliasis patients in 30 countries, and renewed the agreement of donating Egaten in 2018 to 2022 for the treatment of 300,000 patients/year
• Egaten (triclabendazole) is a drug targeted for fascioliasis, registered on WHO Model List of Essential Medicines and has received FDA’s Priority Review voucher based on this approval

Click here to read full press release/ article | Ref: Novartis | Image: Ophthalmology Innovation Summit